top of page

The 13th Annual CEND symposium:

Rapid innovation in a highly regulated space -

What can we learn from COVID-19 for

pandemic preparedness?

4-5 May 2021
Hosted by the Henry Wheeler Center for Emerging and Neglected Diseases
Two Day Conference

This year the Henry Wheeler Center for Emerging and Neglected Diseases will provide a forum for interdisciplinary, science-based discussion to collate “lessons learned” and develop recommendations for future pandemic preparedness. Our schedule includes lectures and interactive workshops. 

The Conference
Featured Speakers

Featured Speakers: 

Janet Napolitano
Professor of Public Policy at the Goldman School of Public Policy, UC Berkeley
How safe are we really? Disaster
preparedness after Covid-19
Janet Napolitano.jpg
Harold varmus.jpeg
Harold Varmus
Professor of Medicine, Weill Cornell Medicine
What urban centers can contribute to pandemic preparedness
Mark McClellan
Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy, Duke University
National Dialogue for Healthcare Innovation: Framework for Private-Public Collaboration on Disaster Preparedness and Response
Barry Bloom.jpeg

Barry Bloom

Harvard T. Chan School of Public Health


Were we prepared for a pandemic?

CEND's Mission

May 4th - Lectures

Jonna Mazet.png

Jonna Mazet

UC Davis One Health Institute

Using a One Health approach to chart a path out of the Pandemic Era

Eva Harris.jpeg

Eva Harris

UC Berkeley Center for Global Public Health

Large-scale serology studies

Lisa Barcellos.jpeg

Lisa Barcellos

UC Berkeley Center for Computational Biology

Large-scale serology studies


Julia Schaletzky

UC Berkeley Center for Emerging and Neglected Diseases

RapidFire: Academic discovery of novel Covid-19 therapeutics

Anders Naar.jpeg

Anders Näär

UC Berkeley Department of Toxicology and Nutrition Sciences

RapidFire: Academic discovery of novel Covid-19 therapeutics

Aashish Manglik.jpeg

Aashish Manglik

UCSF Department of Pharmaceutical Chemistry

RapidFire: Academic discovery of novel Covid-19 therapeutics


Daniel Nomura

UC Berkeley Department of Chemistry


RapidFire: Academic discovery of novel Covid-19 therapeutics


Isaac Ssewanyana


Laboratory Director, National Public Health and Diagnostic Services, Kampala Uganda, Research scientist, Infectious Diseases Research Collaboration

No one is safe until everyone is safe - Development of Covid-19 testing capacity in Uganda

May 5th - Workshops: 


WORKSHOP 1:  Regulatory Science and Pandemic Preparedness – towards “crisis standards of care”

In Emergency Medicine, "crisis standards of care" are well established: Doctors train ahead of time for and have protocols in place how to triage patients in case disaster strikes, ERs are overrun and providers have to quickly decide which heavily injured patient to treat first. However, for other critical elements of pandemic response, i.e. diagnostic testing, manufacturing and supply chain, no such "crisis standards of care" exist. Instead, sometimes overly cautious restrictions are in place that can severely hamper the development of testing capacity during sudden need, i.e. during a pandemic. There is no provision for a sudden increase in need for capacity, breakdown of international supply chains, or a shortage of licensed providers to order and conduct tests and communicate results. How can we use our experience with COVID-19 to inform the generation of a "crisis standard of care" for the regulatory system?   

WORKSHOP 2:  How to refocus research to a new threat rapidly – effective funding mechanisms and science administration to harness reserve capacity

Harnessing National research capacity and allowing investigators to study a new pathogen is a key element of finding a solution to treat and prevent disease and we have seen an unprecedented effort in the science community, including some private sector and grassroots initiatives.  However, the long timelines and risk averse nature of government funding, together with the difficulty to access critical reagents and clinical samples, have slowed down the pivot to COVID-19 research. Also locally, university lab closures and administrative/compliance issues have exacerbated the problem of conducting critical COVID-19 research in a timely fashion. How can we develop systems that allow for a rapid reorientation of research effort in a situation of National need?

WORKSHOP 3: How to accelerate therapeutics development and develop sufficient high containment Drug Discovery laboratory capacity (BSL3/4)

Airborne pathogens, which are the most likely to lead to pandemic spread, require BSL3 or BSL4 containment for research work. BSL3 and BSL4 capacity, both in terms of space and trained personnel, is severely limited, largely confined to academic and government institutions, and cannot support large-scale research and Drug Discovery. In particular, few laboratories can conduct automated high throughput screening in a BSL3 environment. This capacity is very difficult to increase in a timely manner. How can we generate the necessary infrastructure for pandemic preparedness?

If you're interested in learning more about the symposium or CEND, please contact Isabelle Charles at

Subscribe to the CEND newsletter!

CEND Organizing Committee


Michael C. Lu, MD, MS, MPH


UC Berkeley School of Public Health 


Brandie M. Nonnecke, PhD


CITRIS Policy Lab, Carr Center for Human Rights Policy


Celine Perier, PhD

Grant Writer


Stefano M. Bertozzi, MD, PhD

Dean Emeritus

UC Berkeley School of Public Health


Henry Brady, PhD


Goldman School of Public Policy 


Michael Botchan, PhD


Dept. of Molecular and Cell Biology


Luis Lopez

Student Assistant

Shreeya Garg

Student Assistant


Screen Shot 2021-04-02 at 11.46.23
Screen Shot 2021-04-02 at 11.48.59
bottom of page